• Welcome! It’s great to see you. Our forum members are people, maybe like yourself, who experience mental health difficulties or who have had them at some point in their life.

    If you'd like to talk with people who know what it's like

  • Safety Notice: This section on Psychiatric Drugs/Medications enables people to share their personal experiences of using such drugs/medications. Always seek the advice of your doctor, psychiatrist or other qualified health professional before making any changes to your medications or with any questions you may have regarding drugs/medications. In considering coming off psychiatric drugs it is very important that you are aware that most psychiatric drugs can cause withdrawal reactions, sometimes including life-threatening emotional and physical withdrawal problems. In short, it is not only dangerous to start taking psychiatric drugs, it can also be dangerous to stop them. Withdrawal from psychiatric drugs should only be done carefully under experienced clinical supervision.

Physicians, Patients Not Getting Full Information on Antipsychotic Drugs



Well-known member
Mar 23, 2009
Physicians, Patients Not Getting Full Information on Antipsychotic Drugs

Elements of package inserts for second-generation antipsychotic medications aimed at both physicians and patients for use in affective illness “may belie scientific data regarding the neuropsychiatric risks of these drugs,” according to Frederick Jacobsen, M.D., M.P.H., a clinical professor of psychiatry and behavioral sciences at the George Washington University School of Medicine and Health Sciences.

This oversight has significant public health implications, given the increasingly broad prescription of these drugs for mood-related disorders and for off-label uses, wrote Jacobsen in the February issue of the American Journal of Public Health. He reviewed online package inserts for 10 second-generation antipsychotics. Advertisements for the drugs also inaccurately suggest reversibility of chronic neurotoxicty, he wrote.

“Inspection of SGA package inserts ‘Patient Counseling Information’ sections … omit tardive syndromes and other long-term neuropsychiatric side effects," Jacobsen wrote. "These surprising omissions are accompanied by a shift of responsibility for identifying or monitoring long-term neurotoxicity from physician to patient: 7 of 10 SGA package inserts included ‘Medication Guides’ (for patients) that mentioned abnormal movements as potential side effects. Three of these ‘Medication Guides’ instruct patients to ‘notify the prescribing physician if such movements are noticed.’ ”

The lack of appropriate patient counseling may be tied to the brevity of clinical trials (6 to 12 weeks) used for FDA approval compared to the chronic duration of clinical use.

Psych News Alert: Physicians, Patients Not Getting Full Information on Antipsychotic Drugs


Well-known member
Sep 29, 2013
The main thrust of this is side effects from long term use, which is definitely a good point. Just goes to show that it's best not to use prescription drugs over long periods unless there really is no other way.


Hmmm.....I hate to say it....but I will anyway...

"no big surprises there really".....

When are they going to admit the same for SSRIs I wonder?

What does "neurotoxicity" actually mean ?

We need to know.

We are judged by our brain function on these drugs and once off them. If they've caused damage or have the potential to do so, those judgements will never be favourable when we withdraw from these drugs.

How can anyone judge the state of someone's mind accurately with this in the mix....and what hope of recovery does that give?